![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TSC22D2 |
Gene summary for TSC22D2 |
![]() |
Gene information | Species | Human | Gene symbol | TSC22D2 | Gene ID | 9819 |
Gene name | TSC22 domain family member 2 | |
Gene Alias | TILZ4a | |
Cytomap | 3q25.1 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | B4DN36 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
9819 | TSC22D2 | CCI_1 | Human | Cervix | CC | 5.38e-06 | 1.35e+00 | 0.528 |
9819 | TSC22D2 | CCI_2 | Human | Cervix | CC | 3.42e-13 | 1.42e+00 | 0.5249 |
9819 | TSC22D2 | CCI_3 | Human | Cervix | CC | 1.89e-06 | 7.39e-01 | 0.516 |
9819 | TSC22D2 | L1 | Human | Cervix | CC | 1.86e-02 | 2.61e-01 | 0.0802 |
9819 | TSC22D2 | T1 | Human | Cervix | CC | 3.05e-06 | 3.42e-01 | 0.0918 |
9819 | TSC22D2 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.05e-19 | -6.18e-01 | 0.0155 |
9819 | TSC22D2 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.66e-02 | -4.49e-01 | -0.1207 |
9819 | TSC22D2 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.81e-03 | -3.86e-01 | -0.1464 |
9819 | TSC22D2 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.17e-06 | -4.67e-01 | 0.096 |
9819 | TSC22D2 | HTA11_9408_2000001011 | Human | Colorectum | AD | 1.56e-02 | -6.73e-01 | 0.0451 |
9819 | TSC22D2 | HTA11_8622_2000001021 | Human | Colorectum | SER | 9.23e-03 | -6.01e-01 | 0.0528 |
9819 | TSC22D2 | HTA11_10711_2000001011 | Human | Colorectum | AD | 1.49e-04 | -4.71e-01 | 0.0338 |
9819 | TSC22D2 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.07e-14 | -5.51e-01 | 0.0674 |
9819 | TSC22D2 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 9.42e-12 | -4.84e-01 | 0.294 |
9819 | TSC22D2 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.64e-07 | -4.04e-01 | 0.3859 |
9819 | TSC22D2 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 3.26e-02 | -4.60e-01 | 0.2585 |
9819 | TSC22D2 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 2.52e-17 | -5.52e-01 | 0.3005 |
9819 | TSC22D2 | A001-C-207 | Human | Colorectum | FAP | 1.24e-04 | -3.49e-01 | 0.1278 |
9819 | TSC22D2 | A015-C-203 | Human | Colorectum | FAP | 1.78e-23 | -4.72e-01 | -0.1294 |
9819 | TSC22D2 | A015-C-204 | Human | Colorectum | FAP | 6.15e-09 | -4.75e-01 | -0.0228 |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006970 | Colorectum | SER | response to osmotic stress | 23/2897 | 84/18723 | 3.61e-03 | 3.03e-02 | 23 |
GO:00069701 | Colorectum | FAP | response to osmotic stress | 25/2622 | 84/18723 | 1.43e-04 | 2.24e-03 | 25 |
GO:00069704 | Endometrium | AEH | response to osmotic stress | 18/2100 | 84/18723 | 4.94e-03 | 3.12e-02 | 18 |
GO:000697012 | Endometrium | EEC | response to osmotic stress | 19/2168 | 84/18723 | 2.98e-03 | 2.10e-02 | 19 |
GO:00069707 | Esophagus | ESCC | response to osmotic stress | 57/8552 | 84/18723 | 3.26e-05 | 2.70e-04 | 57 |
GO:00069703 | Liver | NAFLD | response to osmotic stress | 20/1882 | 84/18723 | 1.95e-04 | 3.41e-03 | 20 |
GO:000697011 | Liver | Cirrhotic | response to osmotic stress | 34/4634 | 84/18723 | 1.06e-03 | 7.40e-03 | 34 |
GO:00069702 | Liver | HCC | response to osmotic stress | 52/7958 | 84/18723 | 2.58e-04 | 1.92e-03 | 52 |
GO:00069706 | Oral cavity | OSCC | response to osmotic stress | 50/7305 | 84/18723 | 1.11e-04 | 8.15e-04 | 50 |
GO:000697014 | Oral cavity | LP | response to osmotic stress | 32/4623 | 84/18723 | 4.36e-03 | 2.79e-02 | 32 |
GO:00069705 | Prostate | BPH | response to osmotic stress | 27/3107 | 84/18723 | 3.35e-04 | 2.52e-03 | 27 |
GO:000697013 | Prostate | Tumor | response to osmotic stress | 26/3246 | 84/18723 | 1.58e-03 | 9.63e-03 | 26 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TSC22D2 | SNV | Missense_Mutation | c.2204N>A | p.Ser735Tyr | p.S735Y | O75157 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
TSC22D2 | SNV | Missense_Mutation | c.235N>C | p.Glu79Gln | p.E79Q | O75157 | protein_coding | tolerated(0.07) | probably_damaging(0.984) | TCGA-E2-A152-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Targeted Molecular therapy | trastuzumab | PD | |
TSC22D2 | SNV | Missense_Mutation | c.205N>C | p.Glu69Gln | p.E69Q | O75157 | protein_coding | deleterious(0) | probably_damaging(0.991) | TCGA-DR-A0ZM-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unspecific | Cisplatin | SD | |
TSC22D2 | SNV | Missense_Mutation | novel | c.250N>A | p.Val84Ile | p.V84I | O75157 | protein_coding | tolerated(0.06) | benign(0.007) | TCGA-VS-A8QH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Chemotherapy | gemcitabine | PD |
TSC22D2 | SNV | Missense_Mutation | c.805N>G | p.Phe269Val | p.F269V | O75157 | protein_coding | tolerated(0.1) | benign(0.222) | TCGA-AA-3510-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
TSC22D2 | SNV | Missense_Mutation | novel | c.293N>T | p.Ala98Val | p.A98V | O75157 | protein_coding | tolerated(0.08) | benign(0) | TCGA-AA-3947-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
TSC22D2 | SNV | Missense_Mutation | c.2096N>T | p.Ser699Ile | p.S699I | O75157 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
TSC22D2 | SNV | Missense_Mutation | c.2204N>A | p.Ser735Tyr | p.S735Y | O75157 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
TSC22D2 | SNV | Missense_Mutation | novel | c.237G>T | p.Glu79Asp | p.E79D | O75157 | protein_coding | tolerated(0.06) | possibly_damaging(0.727) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
TSC22D2 | SNV | Missense_Mutation | novel | c.565G>A | p.Asp189Asn | p.D189N | O75157 | protein_coding | deleterious(0.01) | probably_damaging(0.909) | TCGA-AA-A02E-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |